EUVIMEDEUVIMED entdecken
Crossref

Pretreatment Tumor-infiltrating CD8 + T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma

Akifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, Taikan Hamamoto, Kazuki Kurosaka, Hideo Suzuki, Yoshihiro Ohishi, Kenta Motomura

Anticancer Research · 2026

DOI: 10.21873/anticanres.18267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Akifumi Kuwano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularLymphocytes, Tumor-InfiltratingCD8-Positive T-LymphocytesAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsAntibodies, MonoclonalHumansFemaleMaleRetrospective StudiesAgedMiddle AgedProgression-Free SurvivalAdult

Stichwörter der Autor:innen

CD8+ T cellsHepatocellular carcinomadurvalumabliver tumor biopsytremelimumabtumor-infiltrating lymphocytes

Substanzen

tremelimumabAntibodies, Monoclonal, HumanizeddurvalumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan; akuwanoh1@aih-net.com.
  • Department of Hepatology, Aso Iizuka Hospital, Iizuka, Japan.
  • Department of Gastroenterology, Ichinomiyanishi Hospital, Ichinomiya, Japan.
  • Department of Diagnostic Pathology, Aso Iizuka Hospital, Iizuka, Japan.

Zitieren

APA

Kuwano, A., Yada, M., Tanaka, K., Hamamoto, T., Kurosaka, K., Suzuki, H., Ohishi, Y., & Motomura, K. (2026). Pretreatment Tumor-infiltrating CD8 + T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.18267

Vancouver

Kuwano A, Yada M, Tanaka K, Hamamoto T, Kurosaka K, Suzuki H, et al. Pretreatment Tumor-infiltrating CD8 + T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma. Anticancer Research. 2026. doi:10.21873/anticanres.18267

BibTeX
@article{Kuwano2026,
  author = {Kuwano, Akifumi and Yada, Masayoshi and Tanaka, Kosuke and Hamamoto, Taikan and Kurosaka, Kazuki and Suzuki, Hideo and Ohishi, Yoshihiro and Motomura, Kenta},
  title = {Pretreatment Tumor-infiltrating CD8 + T Cell Numbers Are Associated With the Response to Tremelimumab Plus Durvalumab in Hepatocellular Carcinoma},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18267}
}
Kostenlos starten →